Plain-English translation of NCT07083882 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach called faecal autologous capsule transplantation — essentially, capsules filled with your own processed gut bacteria — to see if it can help preserve your pancreas's ability to make insulin after a type 1 diabetes diagnosis. Researchers will compare the medication to a placebo (a dummy capsule with no active ingredient) over 6 months, then follow you for another 6 months to see if the benefits last. The goal is to slow or stop the loss of insulin-producing cells in your pancreas, which would help you need less insulin injections and keep your blood sugar more stable.
When type 1 diabetes develops, the immune system mistakenly attacks insulin-producing cells in the pancreas. Recent research suggests that changes in gut bacteria may play a role in this process. This medication aims to restore healthy gut bacteria early after diagnosis, hoping to protect the remaining insulin-producing cells and give your body better control over blood sugar.
You likely qualify if…
You likely don't qualify if…
You would visit the study center a few times over 12 months total. After an initial screening visit, you would take either the medication or a placebo capsule by mouth every day for 6 months, followed by 6 months of follow-up visits. During visits, the researchers will check your blood sugar control, measure how much insulin your pancreas still produces, and ask you about your symptoms and eating habits. Each visit takes about 3 hours, and the study team will also track your blood sugar readings at home using a continuous monitor.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Netherlands